Application No.: 10/773,529 Docket No.: BB1240USCNT

Page 6

REMARKS

Claims 32-44 are now pending, with Claim 32 being the sole independent claim.

Claims 1-31 have been cancelled without prejudice to or disclaimer of the subject matter recited therein.

Claims 32-44 have been added. Support for new claims 32-44 is found in the original claims 1-31 and in the following.

Support in the specification for the percent sequence identity values and the pairwise alignment default parameters cited in claims 32-34 is found at least in the paragraph at page 6, lines 18-32.

Support in the specification for claim 37 is found at least in the paragraph at page 12, lines 22-32.

Support in the specification for the term "recombinant" used in claims 38-44 is found at least in the paragraph at page 10, lines 32-35.

Support in the specification for claims 41-43 is found at least in Examples 5 and 6, pages 20-23.

Support in the specification for claim 44 is found at least in the paragraph at page 14, lines 3-14, and in Example 7, pages 23-24.

No new matter has been added.

The amino acid sequence of SEQ ID NO:12 is encoded by the nucleic acid sequence of SEQ ID NO:11.

Applicants thank the Examiner for the telephone discussions of May 12 and May 17, 2006.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

EMIL M. OROZCO, JR. AGENT FOR APPLICANTS

Registration No. 50,823 Telephone: 302-695-3121 Facsimile: 302-892-1026

Dated: May 17, 2006